Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Hepion Pharmaceuticals Inc (HEPA) USD0.0001

Sell:$1.96 Buy:$2.04 Change: $0.11 (5.85%)
NASDAQ:3.01%
Market closed |  Prices as at close on 1 March 2021 | Switch to live prices |
Sell:$1.96
Buy:$2.04
Change: $0.11 (5.85%)
Market closed |  Prices as at close on 1 March 2021 | Switch to live prices |
Sell:$1.96
Buy:$2.04
Change: $0.11 (5.85%)
Market closed |  Prices as at close on 1 March 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.

Contact details

Address:
399 Thornall St
EDISON
08837-2236
United States
Telephone:
+1 (732) 9024000
Website:
contravir.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
HEPA
ISIN:
US4268971045
Market cap:
$143.30 million
Shares in issue:
76.23 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Gary Jacob
    Chairman of the Board
  • Robert Foster
    Chief Executive Officer, Chief Scientific Officer, Director
  • John Cavan
    Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.